> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Advisory Panel to Discuss Vascepa sNDA
- URL: https://www.fdaweb.com/advisory-panel-to-discuss-vascepa-snda/
- Published: 2019-09-12T12:00:00.000Z
- Updated: 2026-09-15T01:49:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144994

*Federal Register* notice: FDA has announced an 11/14 Endocrinologic and Metabolic Drugs Advisory Committee meeting. Panel members are scheduled to discuss an Amarin Pharma supplemental NDA for Vascepa (icosapent ethyl) capsules for oral administration for reducing the risk of cardiovascular events, as an adjunct to statin therapy in adult patients with elevated triglycerides levels (135 mg/dL or greater) and other risk factors for cardiovascular disease. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-09-12/pdf/2019-19770.pdf?ref=fdaweb.com).